March 20, 2024
Purdue researcher leads teams creating patent-pending smart contacts for glaucoma, neovascularization and dry eyes
$6.7M in federal grants awarded to develop tech to monitor, treat chronic eye diseases
March 20, 2024
A team of researchers from Purdue University, Indiana University School of Optometry and Michigan Medicine have received two grants totaling $6.7 million from the National Eye Institute to further develop specialized smart soft contact lenses that continuously monitor or treat chronic eye diseases.
Purdue University Chi Hwan Lee specialized smart soft contact lenses
March 20, 2024
Research teams at Purdue have been given $6.7 million in grants from the National Eye Institute to develop smart contact lenses that can detect and treat various vision impairments.
March 12, 2024
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the brain and spinal cord which affects approximately 2.5 million individuals worldwide, often striking young adults without warning1,2,3,4. Patients experience a variety of motor, sensory, and cognitive deficiencies1,3,5. Unfortunately, due to the incomplete understanding of the etiology of MS, current available therapies remain largely unsatisfactory, as they mainly focus on immunomodulation or symptomatic relief with limited success2. As such, the long-term trajectory and prognosis for most MS patients, a continual worsening of symptoms until death, is not significantly altered by the current standards of care6,7,8,9,10,11. Thus, a major priority in this field is to identify key pathological factors that can provide new and effective therapeutical targets to deter the pathological progression of MS. There is strong evidence that reactive oxygen species are the mediators of MS pathology12,13,14,15,16. However, antioxidant therapeutic strategies alone have shown limited success in mitigating disease progression14,17,18. Recently, emerging scientific findings suggest that reactive aldehydes, products of free radical-instigated lipid peroxidation, may play a critical role in the pathogenesis of MS19,20,21,22,23. Acrolein, a toxic reactive aldehyde, is both a product and catalyst of oxidative stress and inflammation24,25. As such, it can induce a vicious cycle wherein it begets and worsens the mechanisms by which it is created, thereby amplifying its effects24,25,26. Therefore, acrolein may provide a better target to suppress oxidative stress in MS.
Neuroprotection by acrolein sequestration through exogenously applied scavengers and endogenous enzymatic enabling strategies in mouse EAE model
March 9, 2024
Tao and his associates have begun developing a patent-pending EV method for detecting proteins involved in drug absorption, distribution, metabolism and excretion (ADME). “If successful, this would be tremendously beneficial, especially for drug development companies,” Tao said.
Purdue Researchers Investigate Noninvasive Method For Sampling Drug Response
March 9, 2024
Amplified Sciences, a clinical-stage life sciences diagnostic company that licenses Purdue University innovations, has received $108,000 in two investments from the Flywheel Fund to develop its tests for early, more accurate detection of challenging diseases, starting with pancreatic cancer. Amplified Sciences’ diagnostic tests are based on technology invented by V. Jo Davisson, professor of medicinal chemistry and molecular pharmacology in Purdue University’s College of Pharmacy and a faculty member of the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery. Davisson serves as the company’s chief scientific officer. The company licenses Davisson’s intellectual property through the Purdue Innovates Office of Technology Commercialization.
Purdue University: Amplified Sciences Secures $108K Flywheel Fund Investment For Development Of Pancreatic Cancer Diagnostics
March 8, 2024
Led by Dr. Suresh Mittal, Distinguished Professor of Virology in the Purdue University College of Veterinary Medicine, researchers are working on the development of a universal vaccine, one that would offer protection against all forms of influenza A that infect humans, regardless of the strain. Such a vaccine could eliminate the need to reformulate seasonal flu vaccines and provide the health care system with a jumpstart in combatting the next flu pandemic.
March 8, 2024
An advisory committee has been named to assist in the search for a successor to Dr. Willie Reed, who will step down June 30, after 17 years of leadership as dean of the Purdue University College of Veterinary Medicine and 25 total years of service to the university. A celebration of Dean Reed’s legacy will take place later this semester.
Purdue Launches Search for Successor to Pioneering Veterinary Medicine Dean Willie Reed Who will Step Down
March 8, 2024
Promising initial research could lead to more effective seasonal flu shots and ward against future pandemics
March 6, 2024
In the first experiment of its kind, Purdue University researchers treated canines diagnosed with cancer using chemotherapy to see if their response could lead to future treatment for human cancer patients. Chemoresistance, a patient's adverse reaction to chemotherapy, can lessen remission and survival time. Michael Childress, professor of comparative oncology in the College of Veterinary Medicine at Purdue University, said the dogs were chosen because they had diffuse large B-cell lymphoma. The condition mimics the cancer phenotypes or traits that would be needed when treating human cancer patients.
Purdue researchers see possible link with dog, human cancer treatments
